MHC class I-related chain A (MICA) antigens are surface glycoproteins strongly implicated in innate immunity, and the MICA gene is highly polymorphic. Clinical observations suggest a role for donor MICA antigens expressed on transplant endothelial cells in the alloimmune response, but the effect of MICA genotype is not well understood. Here, we investigated the immunologic effect of the A5.1 mutation, related to the common MICA*008 allele. Compared with wild-type endothelial cells (ECs), homozygosity for MICA A5.1 associated with an endothelial phenotype characterized by 7-to 10-fold higher levels of MICA mRNA and MICA proteins at the cell surface, as well as exclusive release in exosomes instead of enzymatic cleavage. Mechanistically, we did not detect quantitative changes in regulatory microRNAs. Functionally, A5.1 ECs enhanced NKG2D interaction and natural killer cell activation, promoting NKG2D-dependent lysis of ECs. In kidney transplant recipients, polyreactive anti-MICA sera bound preferentially to ECs from MICA A5.1 donors, suggesting that MICA*008(A5.1) molecules are the preferential antigenic determinants on ECs of grafts. Furthermore, the incidence of MICA A5.1 mismatch revealed a statistically significant association between donor MICA A5.1 and both anti-MICA sensitization and increased proteinuria in kidney recipients. Taken together, these results identify the A5.1 mutation as an immunodominant factor and a potential risk factor for transplant survival.
associated with tumor escape 7 but also causes autoreactive T cell stimulation, thus promoting autoimmune diseases. 8 The MICA gene is highly polymorphic, and .70 alleles have been reported so far (http://hla.alleles. org). 9, 10 MICA also has a triplet repeat microsatellite polymorphism (GCT) within exon 5 encoding for the transmembrane region. Seven GCT (alanine) repeats have been described, corresponding to 4(A4), 5(A5), 6(A6), 7 (A7), 8(A8), 9(A9), or 10(A10) alanine repetitions within the transmembrane region. Additionally, a mutation has been associated with certain A5 repeat alleles. This mutation consists of a guanine insertion after the second of five trinucleotide repeats (A5.1) that causes a frameshift mutation leading to a premature intradomain stop codon. 11, 12 Previous studies suggest that MICA A5.1 encodes a truncated protein with possible aberrant protein expression and cellular localization. 13 Although genetic matching of the classic HLA antigens is clearly a major determinant of successful organ transplant outcome, clinical studies demonstrate that MICA is another polymorphic genetic factor involved. Initial studies reported on specific antibodies against MICA in the serum of patients who had rejected kidney allografts, suggesting a role for these molecules in transplant immunopathology. 14, 15 Expression of MICA in transplanted organs has been demonstrated, and anti-MICA antibodies have been associated with both acute and chronic rejection in renal, 16, 17 pancreatic, 18 and heart transplants. 19 In renal transplantation, anti-MICA antibodies after transplantation have been reported in 5%-9% of recipients and cause a 10% decrease in graft survival at 1 year. 20 Together, these findings suggest a role for donor MICA antigens expressed on transplant ECs in the alloimmune response. However, MICA genotyping is not routinely achieved, and a possible correlation between MICA polymorphism, MICA expression, and function on the ECs of the graft is still unknown. Moreover, the molecular bases for MICA allospecific immunization are not well understood.
The aim of this study was to evaluate the functional effect of MICA A5.1 mutation on MICA expression by ECs and its clinical relevance in organ transplantation. Here, we examined the frequency of MICA A5.1 mutation among a cohort of kidney transplant donors. We demonstrate that MICA A5.1 mutation leads to abnormal expression of both surface MICA expression and release of soluble and exosomal MICA antigens by ECs. We show here that endothelial MICA A5.1 expression enhances NKG2D engagement on NK cells and is a major antigenic determinant of the allele-specific anti-MICA humoral response in kidney transplant recipients.
RESULTS

Predominant MICA A5.1 Mutation in Kidney Transplants Is Associated with MICA Protein Alteration in Donor ECs
Cultures of donor ECs corresponding to renal transplantations performed in our institute (ITUN, Nantes, France) between 1999 and June 2012 and prospectively isolated and stored have been used to determine the effect of MICA A5.1 mutation on endothelial phenotype and immune functions. Consistent with our previous study, 21 MICA genotyping of transplant donors (n=84) indicated that A5.1 mutation was associated with four alleles: *023, *028, *053, and *008, the last being the most represented allele in our cohort (34.5%, including MICA*0801 [18.4%] and MICA*0804 [16.1%]) ( Figure 1A) . Overall, the frequency of the MICA A5.1 mutation was 59.5% in our cohort, including 13.1% (n=11) of A5.1 homozygous and 46.4% (n=39) of heterozygous carriers ( Figure 1B) . MICA A5.1 variant contains 5 GCT repeats plus a nucleotide insertion (GGCT) ( Figure 1C ). This insertion causes a frameshift mutation leading to a premature intradomain stop codon within the transmembrane region, which deletes the MICA cytoplasmic tail. As a consequence of this mutation, expression of shortened MICA proteins in EC cultures from A5.1 homozygous donors compared with wild-type (WT) donors (33 kD versus 42 kD, respectively) ( Figure 1D) The NKG2D receptor stimulates activating signals for cytotoxicity by binding NKG2DL (MICA/B or ULBP1/2/3) on target cells. 22 Here, two models were used to study the functional effect of MICA A5.1 EC phenotype. First, coculture of NKL cells with EC monolayers was performed and showed ( Figure 2F ) that elevated MICA cell surface expression on A5.1/A5.1 ECs significantly decreases NKG2D expression on NK cells compared with WT/WT ECs (32.40%66.67% versus 50.80%64.93%; P=0.03), confirming increased ligand/receptor interaction. Second, NK activation and cytotoxic activity toward allogeneic ECs was measured. Enhanced MICA expression at EC target provokes a significant increase in lysis (51.20%611.11% versus 32.96%62.85% of lysis at 100:1 effector cell-to-target cell ratio, for A5.1/A5.1 and WT/WT, respectively; P=0.04) ( Figure 2G ). Together, these findings provide evidence that transplant donors carrying the A5.1 mutation have an elevated expression of MICA protein on the ECs of grafts that triggers an enhanced NKG2D-dependent EC lysis by effector cells.
MICA A5.1 Mutation Changes the Release of Soluble and Exosomal MICA by ECs
A feature of MICA proteins is their ability to be released as soluble form by proteolytic cleavage. 7 To define whether a higher expression of cell-bound MICA may also result in an increased level of soluble MICA (sMICA), EC culture supernatants were collected and sMICA was quantified by ELISA. Unexpectedly, release of sMICA was strongly reduced for MICA A5.1 heterozygous cells (1.82-fold decrease compared with the wild-type [WT] group; P,0.05), whereas almost no soluble form was produced by A5.1 homozygous ECs ( Figure  3A) . Consistent with an impaired shedding of MICA from A5.1 cells, inhibition of metalloproteinases was significantly less efficient to maintain MICA surface expression on A5.1 carriers than on WT ECs (32.5%63.2% versus 119.5%633.8% of basal MICA increase; P=0.03) ( Figure 3B ). A previous study reported the shedding of MICA A5.1 proteins into exosomes 23 as a mechanism of immune escape used by some tumor cell lines. Here, the release of exosomes was similar in quantity from both WT and A5.1 homozygous ECs (3-4 mg/10 6 ECs per 48 hours) ( Figure 3C ). However, consistent with high cell surface expression, immunoblotting indicated that exosomes released from A5.1 ECs expressed higher levels of MICA mutated proteins, with a doseresponse observed for heterozygous and homozygous cells, whereas exosomes from WT ECs were not associated with MICA molecules ( Figure 3D) Figure 4B ).
Among transcriptional mechanisms, regulatory microRNAs (miRNAs) have been recently shown to control basal MICA expression in cells. 24 We found no quantitative change in the miRNAs previously reported to control MICA expression (miR-20a, -106b, -373, -520b) or in miRNAs that we found predicted to target MICA 39UTR (http://www. targetscan.org) (miR-105, -520f, -636) (data not shown). We further speculated that change in MICA A5.1 transcription rate could alternatively result from an associated polymorphism in the promoter region or in the 39UTR region that is a target for miRNA regulatory activity. 25 To test this hypothesis, genomic DNA, in proximal 59 and 39UTRs, from a set of MICA WT (n=24) and A5.1 (n=10) transplant donors was sequenced. As a result, three novel single-nucleotide polymorphisms (SNPs) were identified in the proximal 59 untranslated region (UTR) (at 2364, 2338, and 2308 from start codon), but none were specifically associated with MICA A5.1 ( Figure 4C ). Similarly, seven novel SNPs were found in the MICA 39UTR region (at positions +19, +24, +28, +50, +80, +122, and +157 from the stop codon). Although none were specifically associated with MICA*008(A5.1), we cannot exclude their contribution to regulatory mechanisms.
Graft ECs from MICA A5.1 Donors Are Predominant Targets of Anti-MICA Responses in Kidney Allograft Recipients The prevalence of anti-MICA antibodies after transplantation is around 5%-9%, and the presence of antibodies decreases graft survival by 10% at 1 year after transplantation. 20 To investigate the clinical effect of high MICA expression on graft ECs (i.e., transplant from a MICA A5.1 donor) we analyzed the specificity of anti-MICA responses in a cohort of kidney allograft recipients. Sera from 28 recipients with anti-MICA antibodies in the absence of anti-HLA antibodies were selected for the study. First, antibody specificity for the various MICA alleles of the sera was determined by Luminex assays. Then, we developed an EC cross-match assay (ECXM) to test the MICA-based reactivity of the sera on a cellular relevant target. To this end, sera were incubated with four EC cultures issued from donors homozygous for the four major MICA alleles represented in our donor cohort: MICA*002(WT), MICA*004(WT), MICA*009(WT), and MICA*008(A5.1). A representative example of ECXM positivity is shown in Supplemental Figure 1 . Anti-MICA antibody binding to the various ECs was detected by FACS, as we previously described. 26 Luminex analysis showed that when present in the sera, intensities of anti-MICA*008/ *027 antibodies in the sera were not higher than intensities observed for other anti-MICA antibodies as determined by MFI. When tested on EC cultures expressing physiologic levels of membrane-bound MICA, sera bind only to ECs from MICA*008(A5.1) donors ( Figure 5A) . Surprisingly, similar or even higher antibody levels defined on beads coated with MICA*002, *004, or *009 proteins did not react with EC cultures from MICA*002 (WT), *004(WT), or *009(WT) donors. These findings are illustrated in Figure  5B and Supplemental Figure 2 , which compare the reactivity of a set of recipient's sera on beads and ECs. Together, these data show, for the first time to our knowledge, that anti-MICA antibodies bind to target graft ECs in an allelespecific manner and also suggest that the level of MICA protein on A5.1 mutated EC is a key and limiting parameter. To test this hypothesis, ECXM were repeated on MICA*008 (A5.1) ECs that previously been MICA-silenced using specific small interfering RNA (siRNA) ( Figure 5B) (efficacy of MICA silencing is shown in Supplemental Figure 3) . Here, we demonstrate that reducing MICA level on MICA*008(A5.1) ECs abrogates recipient's sera binding to donor ECs. MICA A5.1 Mismatch between Transplant Donor and Recipient Is a Major Determinant for Anti-MICA Immunization and a Risk Factor for Transplant Outcome As a consequence of the preceding findings attributing to MICA A5.1 changes in graft EC phenotype and function, in circulating forms of MICA released by ECs and the immunodominance of anti-MICA antibodies, we hypothesized that a mismatch in MICA A5.1 between donor (D) and recipient (R), in particular the combination D(A5.1)/R(WT), could promote MICA sensitization. To test this hypothesis, the clinical effect of a MICA A5.1 mismatch was investigated in a cohort of D/R pairs (n=81) with or without post-transplant MICA sensitization, as we previously determined by Luminex single antigen assays. Our threshold for positive MICA sensitization was an MFI ratio $5. Demographic data for both groups are presented in Table 1 . MICA-immunized and MICA-nonimmunized patients in our cohort were selected among transplant recipients with at least 2 years of postgraft follow-up. Follow-up time and time to anti-MICA antibody detection after transplant in our cohort are reported in Table 1 . Genotyping for A5.1 mutation was performed for both donors and recipients. D/R pairs were classified according to their MICA genotypes, and four MICA D/R combinations were defined. The distribution of the D/R combinations was then statistically analyzed in the two groups of patients according to MICA sensitization ( Figure 6 ). Our results show that the combination D A5.1/R WT was overrepresented in the group of MICA-sensitized patients (n=13; 43.3%) compared with the group of nonimmunized recipients. Of note, the D/R full matching for A5.1 was predominant (49.01%) in the nonimmunized patients and low within the MICA-sensitized group (13.3%). Statistical analysis of MICA A5.1 and WT distribution among donors and recipients in both groups demonstrates a significant association between D/R MICA A5.1 mismatch and anti-MICA alloimmunization, particularly when donors carry the A5.1 mutation (P=0.0104).
Clinical and biologic data have been examined and compared according to MICA A5.1 mismatch between donor and recipient, with a particular focus on mismatched D/R pairs in which donors bear the A5.1 mutation. For all patients included in the study, post-transplantation time course of proteinuria, serum creatinine, relative titer of anti-MICA antibodies (expressed as a ratio of MFI), rejection episodes, and C4d deposition were collected and analyzed. Recipients with anti-HLA antibodies (n=8) were excluded from the analysis. Of note, titers of anti-MICA antibodies at peak of immunization seem globally higher in the group of mismatched D/R pairs with donors bearing the A5.1 mutation; there was a 2-to 9-fold increase compared with other groups ( Figure 6B ).
Although not significant because of the small size of our cohort, these data further support the idea that kidney transplants bearing the A5.1 mutation both qualitatively and quantitatively promote anti-MICA immunization. Functionally, we found no significant association with serum creatinine ( Figure 6C ). However, a significant increase in proteinuria concomitant with the peak in anti-MICA antibodies was observed (P=0.03) ( Figure 6D ). Finally, our data suggest a significant correlation between anti-MICA antibody titer (expressed in MFI ratio) and proteinuria (R 2 =0.40; P=0.02) in recipients ( Figure 6E ). This analysis further suggests, in our conditions, an MFI ratio of 50 as a threshold value to reach a clinical effect on proteinuria. Rejection episodes and biopsies have been examined in our cohorts (data not shown). Thirty-five biopsies (24 protocol biopsies and 11 biopsies for diagnosis) have been performed in the nonimmunized group (n=51 recipients). No C4d-positive biopsy was reported in this group. In the MICAimmunized group (n=22 recipients after exclusion of patients with anti-HLA antibodies), 12 biopsies have been done (6 protocol biopsies and 6 biopsies for diagnosis); 3 C4d-positive biopsies have been found. Two of three C4d-positive biopsies correspond to MICA A5.1 transplants in WTrecipients, including one associated with rejection (Banff score, 2b).
DISCUSSION
MICA*008 is the predominant allele in several populations 27, 28 and is consequently highly represented in transplant donor and recipient populations, as demonstrated here. MICA*008 is characterized by a mutation (A5.1) leading to a premature stop codon resulting in a truncated transmembrane and absent cytoplasmic tail. 11 A previous study by Suemizu and colleagues reported on cellular changes associated with MICA A5.1 mutation in epithelial cells. 13 However, except in recent studies, 29, 30 the functional effect of MICA genetic variant and the endothelial expression and regulation of MICA have yet not been explored.
By comparing MICA transcripts and proteins on cultured ECs from WT or MICA A5.1 heterozygous and homozygous donors, we showed that A5.1 mutation causes elevated MICA protein levels in the cell membrane (7-to 10-fold increase versus WT MICA). MICA A5.1 overexpression was not due to an increase in protein stability but rather reflects specific regulatory control at the transcription or post-transcription level. Multiple checkpoints operate to control MICA expression, including post-transcriptional mechanisms that allow faster regulation than could be achieved via transcriptional regulation. Several miRNAs play a key regulatory role in MICA post-transcriptional control. 24 In our study, no significant quantitative change was found for miR-20a, -105, -106b, -373, -520b, -520f, or -636. Nevertheless, we cannot exclude the possibility that cell-specific (i.e., endothelial-specific) miRNAs contribute to MICA regulation in ECs. However, these miRNAs still remain to be identified. We investigated whether a specific polymorphism in the 59 and 39UTR regions of the MICA A5.1-associated alleles could, independently of miRNA level, impair miRNA binding and regulatory action. Genotyping the 59 and 39UTRs from various MICA alleles reveals several SNPs in these regions. However, among the SNPs that we found none was specifically associated with the A5.1 mutation. We speculate that changes in ubiquitination and proteasome degradation processes, previously reported as important events regulating NKG2DL expression 31 altered in cell lines homozygous for MICA*008 allele, 32 could account, at least partially, for accumulated MICA in A5.1 ECs. Functionally, and consistent with a high level of MICA expression, A5.1 ECs increase NKG2D interaction and activity in NK cells compared with ECs expressing full-length MICA. As a consequence, activation of NK cells leads to an elevated NKG2D-dependent lysis of allogeneic A5.1 EC targets. In the transplantation setting, our data suggest that donors bearing the A5.1 allele could be more susceptible to cell lysis mediated by NKG2D-positive effector cells (NK and T CD8+). The role of NK cells in transplant immunology has probably been underestimated, and the contribution of NK cells to graft rejection is an emerging concept supported by recent studies. [33] [34] [35] Our findings support the importance of endothelial expression of polymorphic MICA molecules and of possible mismatch between NK receptors and ligands expressed on recipients and donors, respectively.
Shedding of MICA is a mechanism by which human tumors evade NKG2D-mediated immune destruction. 7, 36 Soluble MICA induces host immune suppression by downregulation of surface NKG2D expression on NK cells and cytotoxic T lymphocytes influencing immune response and patient outcome in cancer 7 and in cardiac transplantation. 37 Exosomes derived from cancer cells also express ligands for NKG2D. 38 Consistent with previous data in a tumor cell line, 23 MICA*008(A5.1) accumulates in the EC supernatant as exosomes and mutated A5.1 ECs fail to release soluble cleaved MICA. We also show, for the first time, that primary ECs secrete large quantities of exosomes (even more than immature dendritic cells 39 ). Palmitoylation of two cysteine residues in the intracellular domain of MICA is necessary for proteolytic shedding of MICA. 40 The absence of these two cysteines in A5.1 mutated proteins could explain the lack of MICA A5.1 protein shedding from ECs. Together, these data suggest that the common MICA*008 (A5.1) allele provides specific immunoregulatory properties to ECs with exacerbated NKG2D interactions mediated via cellular contact but also via exosomes released by ECs. The respective functional effect of soluble versus exosomal MICA remains to be defined. 41 An initial report showing that MICA molecules, expressed at the endothelial cell surface, are recognized by specific antibodies in recipients 14 has been sustained by clinical studies showing the detrimental effect of anti-MICA sensitization in kidney, heart, and lung transplantation. 15, 17, 42, 43 Nevertheless, the molecular basis for MICA alloimmunization remains to be established. 44 Here, we show that MICA A5.1 molecules are primary targets for post-transplant antibodies in kidney allograft recipients because of higher MICA expression associated with this mutation. Our results also indicate that anti-MICA antibodies are alloreactive antibodies that bind to graft ECs in an allele-specific manner. These findings further support a role for MICA*008(A5.1) molecules as major antigenic determinants and targets for recipient sensitization. Clinically, our retrospective cohort study, which aimed to determine the incidence of an A5.1 mismatch, provides the first evidence of a statistically significant association between MICA A5.1 mutation in transplant donors and anti-MICA sensitization of kidney recipients. Further, we observed a statistical correlation between anti-MICA immunization and increased proteinuria in A5.1 mismatched combinations.
To conclude, the A5.1 mutation related to the common MICA*008 allele elicits an endothelial phenotype characterized by an exacerbated expression of MICA at cell surface, the exclusive production of exosomes expressing a high level of MICA as circulating MICA molecules. We propose that MICA mismatch with MICA A5.1 phenotype on the graft ECs in MICA WT recipients promotes NKG2D-dependent effector cellular and anti-MICA humoral responses, suggesting that particular MICA mismatching between donor and recipient may be a risk factor to consider in long-term transplant outcomes.
CONCISE METHODS
Patients and Samples
Since 1999, primary EC cultures at ITUN (Nantes, France) have been prospectively isolated from transplant donors at the time of kidney transplantation and stored for research purposes 26 in the DIVAT Sample Biocollection (French Health Minister project number 02G55).
To investigate the effect of MICA A5.1 mutation on recipient alloimmunization, 81 patients who underwent kidney transplantation between 2001 and 2010 at ITUN (CHU de Nantes, France) were included in the study. This cohort includes 30 D/R pairs with post-transplant anti-MICA antibodies. A control group (n=51) consisted of transplant D/R couples with no antibodies against HLA class I or class II or MICA antigens after transplantation. To allow matching analyses, only D/R pairs with genomic DNA available for MICA typing were selected. Serologic testing for anti-HLA class I and class II and anti-MICA antibodies before and after transplantation was performed by Luminex assays (Labscreen; One Lambda, Canoga Park, CA) at the Laboratoire HLA, EFS Pays de la Loire, Nantes, France.
To evaluate the effect of anti-MICA antibodies on graft function, clinical data, including time to anti-MICA appearance, relative titer of anti-MICA antibodies, serum creatinine, proteinuria, C4d deposition, and rejection episodes, were collected and were available for 14 of the 22 MICA-immunized patients (recipients with anti-HLA antibodies [n=8] were excluded from the analysis). Serum creatinine and proteinuria values were analyzed and compared before and at the time of anti-MICA appearance.
The study was performed according to the guidelines of the local ethics committee (CCPRB, CHU de Nantes, France). Before inclusion of the study, patients consented to the collection and storage of cells and DNA (BioCollection INSERM, French Health Minister project no. 02G55).
EC Isolation and Cell Culture
Isolation and establishment of primary cultures of vascular ECs were performed and characterized as we previously described. 45 ECs were cultured in EC basal medium supplemented with 10% FCS, 0.004 ml/ml EC growth supplement/heparin, 0.1 ng/ml human epidermal growth factor, 1 ng/ml human basic fibroblast growth factor, 1 mg/ml hydrocortisone, 50 mg/ml gentamicin, and 50 ng/ml amphotericin B (C-22010, PromoCell, Heidelberg, Germany). ECs were used between passages 2 and 5. The human NK cell line, NKL, was Values expressed with a plus/minus sign are the mean 6 SD. NA, not applicable. 
Reagents and Antibodies
The following mAbs were used: anti-pan HLA class I (anti-HLA-A, -B, and -C; clone W6/32) (American Type Cell Culture), anti-MICA (AMO1) and MICA/B (BAM01, BAMO3) were for BamOmab (Tubingen, Germany), anti-ULBP1, -2, and -3 (R&D Systems, Lille, France), anti-a5 integrin and anti-glyceraldehyde 3-phosphate dehydrogenase (both from Chemicon, Val de Fontenay, France). Anti-NKG2D mAbs as well as FITC and phycoerythrin-conjugated antimouse F(ab9)2 and antihuman IgG were from Jackson Immunoresearch Laboratories (West Grove, PA). For protein stability analysis, confluent EC monolayers were incubated with cycloheximide (50 mM, Sigma-Aldrich, St. Louis, MO) for the indicated period. For inhibition of soluble MICA release, ECs were treated with galardin (GM6001, 50 mg/ml, Sigma-Aldrich) for the indicated period.
MICA Genotyping, 59 and 39UTR Analysis MICA typing of transplant donors and recipients was performed as we previously described. 21 MICA proximal promoter, exons, and 39UTR region were amplified with the following primers: MICApromo-F59-ACGCGTTGTCTGTCCTGGAA-39, MICApromo-R59-GAGGTGCAAAAGGGAAGATG-39 for the proximal promoter, MICA2-F 59-ATTTCCTGCCCCAGGAAGGTTGG-39 and MICA2-R 59-AGACAGGTCCCTGCTCTCTG-39 for exon2, MICA3-F 59-TTCGGGAATGGAGAAGTCACTGC-39, MICA3-R 59-AAATGCCTT-CATCCATAGCACAG-39 for exon3; MICA4-F 59-GACTTGCA GGTCAGGGGTCCC-39, MICA4-R 59-TGTCCCTACCCTGGCCT-GACC-39 for exon 4, MICA5-F 59-CCTTTTTTTCAGGGAAAGTGC-39, MICA5-R 59-CCTTACCATCTCCAGAAACTGC-39 for exon5, and MICA6-F; 59-GATGTTGATGGAGTGATGGGA-39, MICA6-R; 5-' ATGTTGATCAGGATGGTCTCGATC-39for exon 6 and 59UTR region. PCR for MICA promoter, exons 5 and 6, and 59UTR was performed using 100 ng DNA, 12.5 mM deoxyribonucleotides, 13 Taq buffer, 2 mM MgCl2, 0.1U Taq DNA polymerase (Invitrogen, Carlsbad, CA), and 10 pM of each oligonucleotide. For MICA exons 2, 3, and 4, we first performed PCR using 100 ng DNA, 15 pM of each primer, 46 12.5 mM deoxyribonucleotides, 1 U of Herculase Taq (Stratagene, La Jolla, CA). Then, nested PCR was performed using 1 ml of PCR product and conditions reported above for exons 1, 5, and 6. PCR amplifications were carried out on PTC200 (Bio-Rad Laboratories, Hercules, CA) thermocycler. PCR products were run on 1% agarose gels for control. DNA sequencing was performed (Sequencing Core Facility INSERM/ IFR26, Nantes, France) using a 48-capillary AB 3730 automatic system (Applied Biosystems, Foster City, CA) and analyzed using ChromasPro 1.5 software (Digital River GmbH, Shannon, Ireland).
RNA and Quantitative Real-Time PCR
Total RNA was isolated using the Trizol reagent (Invitrogen). After phenol-chloroform extraction and ethanol precipitation, total RNA (2 mg) was treated with ribonuclease-free Turbo-DNase (Ambion) before reverse transcription. Treated RNA was then reverse-transcripted with Moloney murine leukemia virus reverse transcriptase (Invitrogen) according to the manufacturer's instructions. Real-time quantitative PCR was performed in an ABI PRISM 7900 sequence detection application program using labeled TaqMan probes (Applied Biosystems). The following commercial ready-to-use primers/probe mixes were used (Applied Biosystems): MICA (Hs00792_m1) and hypoxanthine guanine phosphoribosyl transferase (Hs99999909_m1); the latter was used as an endogenous control to normalize RNA amount. Relative expression between a given sample and a reference sample was calculated according to the 2 2DDCt method, in which the reference represents 1-fold expression, as previously described. 47 siRNAs and Silencing siRNAs were designed, synthesized, and purchased from Ambion (Applied Biosystems). Cells were transiently transfected with 25 nM of nontargeting (siCONTROL) or MICA-specific siRNAs (siRNA#s8771, Ambion, Applied Biosystems) using LipofectAMINE RNAiMAX reagent according to the manufacturer's instructions (Invitrogen). The efficiency of silencing, determined by flow cytometry analyses in each experiment, ranged from 70% to 90%.
Immunoblotting
Cells or exosomes were lysed on ice in 20 mmol/LTris-HCl (pH, 7.4), 137 mmol/L NaCl, 0.05% Triton X-100, 1 mmol/L supplemented with protease inhibitors (PIC, Sigma-Aldrich). Deglycosylation with endoglycosidase H and peptide:N-glycosidase F (Sigma-Aldrich) was performed as we described previously. 48 Lysates (20 mg) were resolved by SDS-PAGE (12%) and subjected to Western immunoblot analysis using specific antibodies for MICA/MICB (BAMO1), a5 integrin, or glyceraldehyde 3-phosphate dehydrogenase, as well as secondary horseradish peroxidase-labeled antimouse antibodies (Cell Signaling Technology, St. Quentin-en-Yvelines, France). Antibody-bound proteins were detected using an ECL kit (Amersham) 49 Negative controls were performed using a pool of normal human AB sera from 250 healthy male donors (EFS, Nantes, France) or isotype-matched IgG control (Jackson Immunoresearch Laboratories). Experiments were repeated at least three times. Sera from kidney recipients (n=28) tested in ECXM were provided by Laboratoire HLA (EFS Pays de la Loire, Nantes, France). These sera contain defined anti-MICA as determined by Luminex Single Antigen (LABScreen, One Lambda) but no anti-HLA class I or II antibodies. MICA single antigen kit allows detection of antibodies against MICA*001, *002, *004, *007, *009, *012, *017, *018, *019, and *027. MICA*027 and MICA*008 share the same extracellular region and have been considered equivalent in this study. Fluorescence was measured on 10,000 cells/sample using an FACS (FACScantoII; Becton Dickinson, Mountain View, CA) and analyzed using FlowJo software (Tree Star, Inc., Ashland, OR) and Cytobank. 50 Data are depicted in histograms plotting median ou geomean fluorescence intensity (MFI) on a fourdecade logarithmic scale (x-axis) versus cell number (y-axis).
Cell-Mediated Cytotoxicity Assays
ECs labeled with 51 Cr were incubated with NKL cells for 4 hours at various effector cell-to-target cell ratios. The supernatants were obtained after incubation and being subjected to gamma counting. The maximum or spontaneous release was defined as counts from samples incubated with 5% Triton X-100 or medium alone, respectively. Cytolytic activity was calculated with the following formula:
%lysis ¼ ðexperimental release 2 spontaneous releaseÞ 3100=ðmaximum release 2 spontaneous releaseÞ:
The spontaneous release in all assays was ,20% of the maximum release.
Soluble MICA and Exosome Analysis
Detection of sMICA was done using a sandwich ELISA from BamoMab (Tubingen, Germany). For exosome purification, confluent EC monolayers were cultured in EC basal medium without serum or growth factor supplementation for 48 hours. Cell culture media were centrifuged twice for 10 minutes at 300 g and then centrifuged for 30 minutes at 10,000 g. Supernatants were centrifuged for 70 minutes at 100,000 g. Pellets containing exosomes were washed in PBS and centrifuged for 70 minutes at 100,000 g. Exosomes were stored at 280°C before analysis.
Statistical Analyses
The data are expressed as mean 6 SEM and compared using nonparametric Mann-Whitney test or Kruskal-Wallis test (with Dunn multiple comparison post-test) if there were more than two conditions. Statistical analysis of the association between D/R MICAWTor A5.1 genotype mismatch and MICA alloimmunization was performed using Pearson chi-squared test. A correlation analysis between serum anti-MICA relative titer and proteinuria was performed using linear regression analysis and Pearson correlation. Statistical analysis was performed using GraphPad Prism software (GraphPad, San Diego, CA). A P value ,0.05 was considered to represent a statistically significant difference. In all figures, one asterisk (*) denotes P,0.05, two asterisks (**) denotes P,0.01, three asterisks denotes P,0.001.
